Please use this identifier to cite or link to this item:
http://hdl.handle.net/2080/5210
Title: | Lysosome-Targeting Morpholine-Derived Thiosemicarbazone-Based Ru(III) Complex as Anticancer Agents |
Authors: | Das, Sanchita Dinda, Rupam |
Keywords: | ruthenium(III) thiosemicarbazones morpholine anticancer activity lysosome-targeting |
Issue Date: | Jun-2025 |
Citation: | International Conference on Peptide and Protein Metalation, University of Naples, Naples, Italy, 10-12 June 2025 |
Abstract: | The strategy of coordinating biologically active luminogenic ligand systems to ruthenium metal centers to exploit their synergistic effects has gained significant momentum in order to develop them as promising theranostic agent. Also, there are many ruthenium(III) complexes such as KP1019, NKP-1339, and IT-139 that have progressed into the human and clinical trials creating opportunities for the development of novel anticancer agents. On the other hand, incorporating luminescent ligand systems could enhance the overall fluorescence properties of complex, enabling its use as a bioimaging probes for detecting various cellular functions at a subcellular level. Thiosemicarbazones (TSCs) come under such category of ligand systems. The morpholine unit containing a weakly basic moiety (-NH) allows to protonate in an acidic environment of organelles making it particularly effective for lysosome targeting. In this context, three RuIII complexes (1−3) featuring morpholine-derived thiosemicarbazone ligands have been reported along with the structures properly characterized using various spectroscopy techniques. Theirsolution stability has been explored using conventional techniques such as UV−vis and HRMS.1To gain insight into their mechanism of action, the cytotoxicity, hydrophobicity, and the interaction of complexes with DNA and HSA were evaluated by different conventional methods.2 Along with favorable biomolecule interaction, 1−3 revealed potent selectivity toward cancer cells, which is a prerequisite for the generation of an anticancer drug. Additionally, the fluorescence-active ruthenium complexes selectively target lysosomes, which is evaluated by livecell imaging. 1−3 disrupt the lysosome membrane potential by generating an excessive amount of reactive oxygen species, which results in an apoptotic mode of cell death |
Description: | Copyright belongs to proceeding publisher |
URI: | http://hdl.handle.net/2080/5210 |
Appears in Collections: | Conference Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2025_PPM_SDas_Lysosome-Targeting.pdf | Poster | 1.27 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.